Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors

Platelets

Volumn 22, Issue 5, 2011, Pages 338-344

  Kobzar, Gennadi ^a   Mardla, Vilja ^a   Samel, Nigulas ^a  

^a TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

Author keywords

Aspirin resistance; cyclooxygenase inhibitors; glucose; lactic acid; platelets

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHALASIN B; FRUCTOSE; GALACTOSE; GLUCOSE; IBUPROFEN; INDOMETACIN; LACTIC ACID; N(G) METHYLARGININE; PARACETAMOL; PHLORETIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; ANAEROBIC GLYCOLYSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ACETAMINOPHEN; ADENOSINE DIPHOSPHATE; ADULT; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CELLS, CULTURED; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; HUMANS; INDOMETHACIN; LACTIC ACID; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET-RICH PLASMA;

EID: 80051531710     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.535931     Document Type: Article

References (20)

1. Riondino S, Trifirò E, Principessa L, Mascioletti S, Di Renzo L, Gaudio C, et al. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production. Thromb Res 2008;122:359-365.
2. Capone ML, Tacconelli S, Francesco LD, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007;82:85-94. (Pubitemid 44895440)
3. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, on behalf of the PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003;26:3264-3272.
4. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atheroclerotic events in patients with type 2 diabetes. JAMA 2008;300:2134-2141.
5. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J 2009;30:1279-1286.
6. Pinckard RN, Hawkins D, Farr RS. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 1968;219:68-69.
7. Contreras I, Reiser KM, Martinez N, Giansante E, Lopez T, Suarez N, et al. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care 1997;20:832-835. (Pubitemid 27202537)
8. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005;83:148-158. (Pubitemid 40379303)
9. De La Cruz JP, Arrebola MM, Villalobos MA, Pinacho A, Guerrero A, González-Correa JA, Sánchez de la Cuesta F. Influence of glucose concentration on the effects of aspirin, ticlopidine and clopidogrel on platelet function and plateletsubendothelium interaction. Eur J Pharmacol 2004;484:19-27. (Pubitemid 38068530)
10. Le Guyader A, Pacheco G, Seaver N, Davis-Gorman G, Copeland J, McDonagh PF. Inhibition of platelet GPIIb-IIIa and P-selectin expression by aspirin is impaired by stress hyperglycemia. J Diabetes Complications 2009;23:65-70.
11. O'Kane PD, Queen LR, Ji Y, Reebye V, Stratton P, Jackson G, Ferro A. Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res 2003;59:152-159. (Pubitemid 36776381)
12. O'Kane P, Xie L, Liu Z, Queen L, Jackson G, Ji Y, Ferro A. Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity. Cardiovasc Res 2009;83:123-130.
13. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003;14:421-427. (Pubitemid 38096113)
14. Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK. The role of nitric oxide in aspirin induced thrombolysis in vitro and the purification of aspirin activated nitric oxide synthase from human blood platelets. Am J Hematol 2007;82:986-995. (Pubitemid 350004390)
15. Chen L, Salafranca MN, Mehta JL. Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets. Am J Physiol 1997;273:H1854-H1859.
16. Takahara K, Murray R, FitzGerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990;265:6836-6844.
17. Ferreira IA, Mocking AI, Urbanus RT, Varlack S, Wnuk M, Akkerman JW. Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B. J Biol Chem 2005;280:32625-32633. (Pubitemid 41368305)
18. Akkerman JWN. Regulation of carbohydrate metabolism in platelets. A Review. Thromb Haemost 1978;39:712-724. (Pubitemid 9016366)
19. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999;339:607-614. (Pubitemid 29243524)
20. Heijnen HF, Oorschot V, Sixma JJ, Slot JW, James DE. Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from alpha-granules to the cell surface. J Cell Biol 1997;138:323-330.(Pubitemid 27323534)